Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.